Senate Files

Bills

S. 2780 118th Congress

Medication Affordability and Patent Integrity Act

Latest action, Sep 13, 2023: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

How the Senate voted

The Senate hasn't taken a roll call on this bill in the Congresses covered.

1 cosponsor

Sponsored by Margaret Wood Hassan (Democrat). Cosponsors by party, House members included:

  • Democrats
  • Republicans
  • Independents
Cosponsors
0 D · 1 R
  • Democrat
  • Republican
  • Independent
1 senators cosponsoring

Referred to: Senate: Health, Education, Labor, and Pensions Committee

Who lobbied on it

Clients whose quarterly lobbying reports named it, each quarter.

31 clientsQ3 2023Q4 2024

The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.

FRESENIUS KABI USA LLC
WEST FRONT STRATEGIES LLC
6 reports
GSK (FKA GLAXOSMITHKLINE INC.)
6 reports
NATIONAL MULTIPLE SCLEROSIS SOCIETY
6 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
6 reports
VIATRIS INC
WEST FRONT STRATEGIES LLC
6 reports
ASSOCIATION FOR ACCESSIBLE MEDICINES
5 reports
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)
WHITMER & WORRALL, LLC
5 reports
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC
COVINGTON & BURLING LLP
4 reports
THE CAMPAIGN FOR SUSTAINABLE RX PRICING
MEHLMAN CONSULTING, INC.
4 reports
AARP
3 reports
AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION (AIPLA)
3 reports
BIOTECHNOLOGY INNOVATION ORGANIZATION
3 reports
VIATRIS INC
3 reports
ABBVIE INC.
2 reports
AMGEN INC
2 reports
All 25 of 33 clients
ClientLobbying firmReportsReports totalingFromToSenate
FRESENIUS KABI USA LLCWEST FRONT STRATEGIES LLC6$0Q4 2023Q3 2024yes
GSK (FKA GLAXOSMITHKLINE INC.)6$7.3MQ4 2023Q3 2024yes
NATIONAL MULTIPLE SCLEROSIS SOCIETY6$393KQ4 2023Q3 2024yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA6$43.8MQ4 2023Q3 2024yes
VIATRIS INCWEST FRONT STRATEGIES LLC6$0Q4 2023Q3 2024yes
ASSOCIATION FOR ACCESSIBLE MEDICINES5$3.0MQ4 2023Q3 2024yes
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)WHITMER & WORRALL, LLC5$120KQ4 2023Q3 2024yes
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INCCOVINGTON & BURLING LLP4$0Q3 2023Q3 2024yes
THE CAMPAIGN FOR SUSTAINABLE RX PRICINGMEHLMAN CONSULTING, INC.4$230KQ1 2024Q3 2024yes
AARP3$13.8MQ4 2023Q3 2024yes
AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION (AIPLA)3$20KQ3 2023Q3 2024yes
BIOTECHNOLOGY INNOVATION ORGANIZATION3$4.9MQ4 2024Q3 2024yes
VIATRIS INC3$1.9MQ3 2023Q3 2024yes
ABBVIE INC.2$2.4MQ4 2024Q3 2024yes
AMGEN INC2$5.5MQ4 2024Q3 2024yes
AMNEAL PHARMACEUTICALS2$440KQ4 2024Q3 2024yes
CHAMBER OF COMMERCE OF THE U.S.A.2$37.2MQ4 2024Q3 2024yes
COUNCIL FOR INNOVATION PROMOTION (C4IP)2$100KQ4 2024Q3 2024yes
COUNCIL FOR INNOVATION PROMOTION (C4IP)RADIUS ADVOCACY, LLC2$0Q4 2024Q3 2024yes
INTELLECTUAL PROPERTY OWNERS ASSOCIATION2$80KQ4 2024Q3 2024yes
NOVARTIS2$1.5MQ4 2024Q3 2024yes
PATIENTS RISING NOWYC CONSULTING, LLC2$160KQ4 2024Q3 2024yes
PFIZER INC.2$2.7MQ4 2024Q3 2024yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICACROSSROADS STRATEGIES, LLC2$0Q4 2024Q3 2024yes
THE ERISA INDUSTRY COMMITTEEMEHLMAN CONSULTING, INC.2$0Q4 2024Q3 2024yes